• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Researchers unlock an immunity ‘black box’

Bioengineer by Bioengineer
April 18, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A research team led by St. Jude Children's Research Hospital immunologists has revealed a previously unknown immune machinery that goes awry to trigger the inflammatory disease neutrophilic dermatosis. Neutrophilic dermatoses are a heterogeneous group of autoinflammatory skin disorders that include Sweet's syndrome, pyoderma gangrenosum, and subcorneal pustular dermatosis and may occur with cancers such as leukemia as well as infections or inflammatory bowel disease.

Mapping the biological machinery underlying the disease's inflammation is important because there are no drugs that specifically target the wide array of similar autoinflammatory diseases. Autoinflammatory diseases occur when the hyperactive innate immune system attacks the body.

Currently, the only treatments for such disorders are strong immunosuppressive drugs that also render patients susceptible to infection.

The study was led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology. The findings appear today in the journal Immunity. First authors were Prajwal Gurung, Ph.D., a postdoctoral fellow in the Kanneganti laboratory, and Gaofeng Fan, Ph.D., of Cold Spring Harbor Laboratory.

Abnormalities in the PTPN6 gene have been implicated in human diseases such as pyoderma gangrenosum, multiple sclerosis, leukemia and psoriatic arthritis.

The researchers used a strain of gene-altered mouse in which the activity of a protein encoded by the Ptpn6 gene was "dialed down." The mice developed inflammatory skin disease similar to neutrophilic dermatosis in humans. Like humans with the disorder, the mice appear normal when first born, but as they age, they developed the inflammatory disease.

How does disease ensue in the Ptpn6 mutant mice? What are the key pathways that are regulated by the Ptpn6 gene? Kanneganti and her colleagues previously discovered in a seminal study published in Nature that IL-1 alpha is the key master regulator that provokes uncontrolled immune response in the Ptpn6 mutant mice. But the machinery linking Ptpn6 and IL-1 alpha was a "black box," Kanneganti said.

To map the machinery, the researchers took a genetic approach and painstakingly produced mice defective in Ptpn6 that additionally lacked candidate genes in the pathway. Here, the researchers knew that if the Ptpn6 mutant mice crossed with the mouse deficient in a candidate gene do not develop disease, they would be able to identify the gene that triggers aberrant inflammation and disease. After creating some 50 different combinations with different candidate genes, the researchers pieced together the puzzle of the immune machinery underlying the inflammation.

The picture they revealed further confirmed that IL-1 alpha is a master immune switch that activates the machinery. In addition, they also identified several key molecules including RIPK1, TNF, TAK1 and SYK that drive inflammation and tissue damage.

"This is quite an important finding," Kanneganti said. "IL-1 alpha was discovered more than 45 years ago, but we have not known how it is regulated and how it functions. And our lab is one of the very few in the country studying IL-1 alpha."

The finding of IL-1 alpha's role, as well as many other molecular switches in the immune machinery, will offer multiple targets for developing drugs to switch off the uncontrolled immune response in inflammatory diseases, Kanneganti said. "In this particular study, we have identified several prime drug targets for molecules involved in the pathway, especially IL-1 alpha," she said.

Another important finding is how different "cellular compartments" interact to trigger autoinflammatory disease. While the abnormal Ptpn6 gene functions in the bone marrow–a major source of disease instigating innate immune cells–the IL-1 alpha master switch functions in the skin.

"This told us that cross talk between cells is really critical in mediating this disease," Kanneganti said. "It gives us important information about how the immune system works both to drive autoinflammatory disease and to fight infection. And it illustrates why we could not have studied this process in a cell culture system but needed to study it in a mouse model."

Finally, the study unraveled how the Ptpn6 gene regulates IL-1 alpha mediated aberrant inflammation and disease. The researchers identified that Ptpn6 inhibited activation of a critical tyrosine kinase called SYK to modulate activation of a central adaptor protein MyD88, a previously unknown signaling node. Given the central role of MyD88 in inflammation, these data are relevant not only to neutrophilic dermatosis but also to several other inflammatory diseases and will spur several new studies.

###

The other authors were John Lukens of the University of Virginia Charlottesville, Peter Vogel of St. Jude and Nicholas Tonks of Cold Spring Harbor.

Their work was supported in part by grants (CA53840, GM55989, CA163507, AR056296, AI124346, AI101935, CA021765-35) from the National Institutes of Health and ALSAC, the fundraising and awareness arm of St. Jude.

Media Contact

Jann Ingmire
[email protected]
901-595-6384
@StJudeResearch

http://www.stjude.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Genetic “Trojan Horse” Targets and Destroys Cancer Cells Associated with Kaposi’s Sarcoma

Genetic “Trojan Horse” Targets and Destroys Cancer Cells Associated with Kaposi’s Sarcoma

October 1, 2025
Revolutionary Organic Molecule Poised to Transform Solar Energy Harvesting

Revolutionary Organic Molecule Poised to Transform Solar Energy Harvesting

October 1, 2025

Rhythmic Predictions Enhance Acoustic-Semantic Speech Processing

October 1, 2025

MSK Researchers Pioneer Innovative Method to Investigate Treatment Resistance in High-Grade Serous Ovarian Cancer

October 1, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    90 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    63 shares
    Share 25 Tweet 16
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    61 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Genetic “Trojan Horse” Targets and Destroys Cancer Cells Associated with Kaposi’s Sarcoma

Revolutionary Organic Molecule Poised to Transform Solar Energy Harvesting

Rhythmic Predictions Enhance Acoustic-Semantic Speech Processing

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.